Mechanistically, activation of caspase-3, suppression of anti-apoptotic BCL2 and BCL-XL expression, and increased PARP cleavage were detected in pancreatic cancer cells upon treatment with low doses of 2d. The gene discussed is BCL2L1; the disease is pancreatic neoplasm.